Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp426 | Osteoporosis: treatment | ECTS2013

Characterization and incidence on acute phase reaction in Paget's disease after zoledronic acid infusion

Mateos A Conesa , Sala D Rotes , Abello J Carbonell

Zoledronic acid (AZ), is considered first-line treatment for Paget’s disease (PD) of bone. The most common adverse event is flu-like syndrome, described between 10 and 50% of patients. Nowadays, there is not known exactly the molecular basis of this syndrome yet. Statins play an important role in the mevalonate pathway, blocking the production of proinflammatory cytokines secreted by T cells γ/δ.Objectives: Characterization and in...

ba0001pp428 | Osteoporosis: treatment | ECTS2013

Persistence with different anti-osteoporosis medications: a population-based cohort study.

Pages-Castella Aina , Carbonell-Abella Cristina , Nogues Xavier , Javaid M Kassim , Arden Nigel K , Cooper Cirus , Diez-Perez Adolfo , Prieto-Alhambra Daniel

Objective: Several reports suggest very low persistence with oral bisphosphonates, but there is a scarcity of data on persistence with other anti-osteoporosis medications. We therefore compared rates of early discontinuation (in the first year of therapy) between all available outpatient anti-osteoporosis drugs in Catalonia, Spain.Study design: population-based retrospective cohort study.Participants and source of data: The data in...

ba0002p163 | (1) | ICCBH2013

Phenotype–genotype correlation and role of ancillary investigations in atypical and rare forms of osteogenesis imperfecta

Balasubramanian Meena , Parker Michael , Bishop Nicholas J

Background: Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. It is a variable condition with a range of clinical severity. About 90% of patients with a clinical diagnosis of OI have a mutation in the COL1A1 or COL1A2 genes, which shows an autosomal dominant pattern (AD) of inheritance. Other genes are associated with the autosomal recessive (AR) ...

ba0001oc5.4 | Treatment of osteoporosis | ECTS2013

Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis

Graeff C , Campbell G , Pena J , Padhi D , Grossman A , Chang S , Libanati C , Gluer C-C

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...

ba0002p18 | (1) | ICCBH2013

Influence of anthropometric parameters on assessment of paediatric bone mineral density and bone mineral content

Hangartner Thomas N , Short David F , Gilsanz Vicente , Kalkwarf Heidi J , Lappe Joan M , Oberfield Sharon , Shepherd John A , Zemel Babette S , Winer Karen

Objectives: Creation of reference curves for areal bone mineral density (aBMD) and bone mineral content (BMC) with consideration of relevant anthropometric variables.Methods: Analysis of the dual-energy X-ray absorptiometry (DXA) data collected as part of the Bone Mineral Density in Childhood Study1, including 2012 boys and girls, 5–22 years old, with a total of 10 525 visits, resulting in aBMD and BMC observations at the lumbar spine, hi...

ba0006p145 | (1) | ICCBH2017

Longitudinal growth and bone development in glucocorticoid treated boys with Duchenne muscular dystrophy

Joseph S , Capaldi N , DiMarco M , Dunne J , Horrocks I , Shepherd S , Ahmed S F , Wong S C

Background: There is still limited information on changes in growth especially segmental growth and bone mass of glucocorticoid(GC) treated boys with Duchenne Muscular Dystrophy (DMD).Objectives: To evaluate changes in growth and bone mass in GC treated boys with DMD.Methods: Retrospective study of 15 boys with DMD treated with GC, median age 7.6 years (4.1, 15.5) who had repeated DXA scan for clinical monitoring of bone health, me...

ba0006p065 | (1) | ICCBH2017

A novel form of congenital rickets due to a recurrent gain of function mutation in CYP3A4

Rodda Christine P , Levine Michael A , Roizen Jeffrey D , Javaid Muhammad K , Ebeling Peter R , Nguyen Hanh , Dewez Peter , Shaw Nicholas J

Although Vitamin D deficiency is the most common form of rickets worldwide, when there is a failure to respond to cholecalciferol, inborn errors of vitamin D metabolism should be considered. We describe two unrelated individuals who presented with early onset rickets characterised by reduced serum levels of 25(OH)D and 1,25(OH)2D, and a deficient response to Vitamin D2/D3 and calcitriol. Case 1: A Caucasian Australian girl with non-consanguineous parents ...

ba0001pp245 | Cell biology: osteocytes | ECTS2013

IGF1 regulates MC-3T3 and human primary osteoblast to osteocyte differentiation in 3D culture

Scully Nicole E E , Mason Deborah J , Evans Bronwen A J

Osteocytes differentiate from osteoblasts, are embedded in mineralised matrix and are critical regulators of bone remodelling. In vitro osteocyte models are limited to cell lines in monolayer, which do not represent their 3D environment in vivo. We have shown that osteoblasts in 3D gels differentiate along the osteocytic pathway. Since IGF1 regulates osteoblasts, and is involved in osteocyte response to mechanical loading, we hypothesised that IGF1 modulates ...

ba0002p21 | (1) | ICCBH2013

Bone disease in children with geroderma osteodysplasticum: a 25-year experience from a single tertiary centre

Gopal-Kothandapani J S , Padidela R , Clayton-Smith J , Chandler K E , Adams J E , Freemont A J , Mughal M Z

Geroderma osteodysplasticum (GO) is a rare autosomal recessive connective tissue disorder characterised by progeria like facies, wrinkled lax skin, joint hypermobility, congenital dislocation of hips and propensity to fragility fractures. In the past 25 years, five patients (three females and two males) diagnosed with GO were referred to our Paediatric metabolic bone service for assessment and management of secondary bone problems. All five children were born to consanguineous...